Efficacy of a Non-Hormonal Treatment, BRN-01, on Menopausal Hot Flashes
Homeopathic medicines have a place among the non-hormonal therapies for the treatment of hot flashes during the menopause.
The objective of this study was to evaluate the efficacy of the non-hormonal treatment BRN-01 in reducing hot flashes in menopausal women.
This was a multicenter, randomized, double-blind, placebo-controlled study carried out between June 2010 and July 2011.
The study was conducted in 35 active centers in France (gynecologists in private practice).
One hundred and eight menopausal women, ≥50 years of age, were enrolled in the study. The eligibility criteria included menopause for <24 months and ≥5 hot flashes per day with a significant negative effect on the women’s professional and/or personal life.
Treatment was either BRN-01 tablets, a registered homeopathic medicine containing Actaea racemosa (4 centesimal dilutions [4CH]), Arnica montana (4CH), Glonoinum (4CH), Lachesis mutus (5CH), and Sanguinaria canadensis (4CH), or identical placebo tablets, prepared by Laboratoires Boiron according to European Pharmacopoeia standards. Oral treatment (2 to 4 tablets per day) was started on day 3 after study enrollment and was continued for 12 weeks.
Main Outcome Measure
The main outcome measure was the hot flash score (HFS) compared before, during, and after treatment. Secondary outcome criteria were the quality of life (QoL) [measured using the Hot Flash Related Daily Interference Scale (HFRDIS)], severity of symptoms (measured using the Menopause Rating Scale), evolution of the mean dosage, and compliance. All adverse events (AEs) were recorded.
One hundred and one women were included in the final analysis (intent-to-treat population: BRN-01, n = 50; placebo, n = 51). The global HFS over the 12 weeks, assessed as the area under the curve (AUC) adjusted for baseline values, was significantly lower in the BRN-01 group than in the placebo group (mean ± SD 88.2 ± 6.5 versus 107.2 ± 6.4; p = 0.0411). BRN-01 was well tolerated; the frequency of AEs was similar in the two treatment groups, and no serious AEs were attributable to BRN-01.
BRN-01 seemed to have a significant effect on the HFS, compared with placebo. According to the results of this clinical trial, BRN-01 may be considered a new therapeutic option with a safe profile for hot flashes in menopausal women who do not want or are not able to take hormone replacement therapy or other recognized treatments for this indication.
Trial registration number (EudraCT): 2009-016959–21.
- Holte, A. (1991) Prevalence of climateric complaints in a representative sample of middle-aged women in Oslo, Norway. Obstet Gynaecol 12: pp. 303-17
- Agence Nationale d’Accréditation et d’Evaluation en Sante (ANAES), Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). Traitements hormonaux substitutifs de la menopause: orientations générales conclusions et recommandations, 11 Mai 2004 [online]. Available from URL: http://www.has-sante.fr/portail/upload/docs/application/pdf/ths_rapport_final_corrige_mtev_-_orientations_generales_2006_10_25_15_41_5_415.pdf [Accessed 2012 Jun 1]
- Deecher, D.C., Dorries, K. (2007) Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and post-menopause life stages. Arch Womens Ment Health 10: pp. 247-57 CrossRef
- Archer, D.F., Sturdee, D.W., Baber, R. (2011) Menopausal hot flushes and night sweats: where are we now?. Climacteric 14: pp. 515-28 CrossRef
- Nelson, H.D. (2008) Menopause. Lancet 371: pp. 760-70 CrossRef
- MacLennan, A.H., MacLennan, A., Wenzel, S. (1993) Continuous low-dose estrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 159: pp. 102-6
- Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). Mise au point actualisée sur le traitement hormonal substitutif de la ménopause (THS) — Décembre 2003 [online]. Available from URL:http://www.ansm.sante.fr/var/ansm_site/storage/original/application/5f1077b7c7017dcbeb42dbc7942363f5.txt [Accessed 2012 Jun 1]
- Kelley, K.W., Carroll, D.G. (2003) Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women. J Am Pharm Assoc 50: pp. e106-15
- Chlebowski, R.T., Hendrix, S.L., Langer, R.D. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 289: pp. 3243-53 CrossRef
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291: pp. 1701-12 CrossRef
- Rossouw, J.E., Anderson, G.L., Prentice, R.L. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: pp. 321-33 CrossRef
- Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: pp. 419-27 CrossRef
- Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: pp. 1543-51 CrossRef
- Utian, W.H., Archer, D.F., Bachmann, G.A. (2008) Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 15: pp. 584-602
- Schonberg, M.A., Davis, R.B., Wee, C.C. (2005) After the Women’s Health Initiative: decision making and trust of women taking hormone therapy. Womens Health Issues 15: pp. 187-95 CrossRef
- McIntyre, R.S., Konarski, J.Z., Grigoriadis, S. (2005) Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship. CMAJ 172: pp. 57-9
- Brett, K.M., Keenan, N.L. (2007) Complementary and alternative medicine use among midlife women for reasons including menopause in the United States: 2002. Menopause 14: pp. 300-7 CrossRef
- Nelson, H.D., Vesco, K.K., Haney, E. (2006) Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295: pp. 2057-71 CrossRef
- Archer, D.F., Seidman, L., Constantine, G.D. (2009) A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 200: pp. 172.e1-10 CrossRef
- Speroff, L., Gass, M., Constantine, G. (2008) Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 111: pp. 77-87 CrossRef
- Archer, D.F., Dupont, C.M., Constantine, G.D. (2009) Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo controlled trial of efficacy and safety. Am J Obstet Gynecol 200: pp. 238.e1-10 CrossRef
- Evans, M.L., Pritts, E., Vittinghoff, E. (2005) Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 105: pp. 161-6 CrossRef
- Suvanto-Luukkonen, E., Koivunen, R., Sundstrum, H. (2005) Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo controlled, double-blind study. Menopause 12: pp. 18-26 CrossRef
- Loprinzi, C.L., Sloan, J., Stearns, V. (2009) Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 27: pp. 2831-7 CrossRef
- Reddy, S.Y., Warner, H., Guttuso, T. (2006) Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 108: pp. 41-8 CrossRef
- Albertazzi, P., Bottazzi, M., Purdie, D.W. (2003) Gabapentin for the management of hot flushes: a case series. Menopause 10: pp. 214-7 CrossRef
- Demarque D, Jouanny J, Poitevin B, et al. Pharmacologie et matière médicale homéopathique. 3rd ed. Paris: Editions CEDH (Centre d’Enseignement et de Developpement de L’homeopathie), 2003
- Guermonprez M, Pinkas M, Torck M. Matière médicale homéopathique. 2nd ed. Sainte Foy-lès-Lyon: Edition Boiron, 1997
- Relton, C., Weatherley-Jones, E. (2005) Homeopathy service in a National Health Service community menopause clinic: audit of clinical outcomes. J Br Menopause Soc 11: pp. 72-3 CrossRef
- Bordet, M.F., Colas, A., Marijnen, P. (2008) Treating hot flushes in menopausal women with homeopathic treatment: results of an observational study. Homeopathy 97: pp. 10-5 CrossRef
- Carpenter, J.S. (2001) The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 22: pp. 979-89 CrossRef
- Heinemann, L.A.J., Potthoff, P., Schneider, H.P.G. (2003) International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes 1: pp. 28 CrossRef
- Sloan, J.A., Loprinzi, C.L., Novotny, P.J. (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19: pp. 4280-90
- MacLennan, A.H., Broadbent, J.L., Lester, S. (2004) Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 4: pp. CD002978
- Freeman, E.W., Sherif, K. (2007) Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 10: pp. 197-214 CrossRef
- Benigni, J.P., Allaert, F.A., Desoutter, P. (2011) The efficiency of pain control using a thigh pad under the elastic stocking in patients following venous stripping: results of a case-control study. Perspect Vasc Surg Endovasc Ther 23: pp. 238-43 CrossRef
- Efficacy of a Non-Hormonal Treatment, BRN-01, on Menopausal Hot Flashes
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Drugs in R&D
Volume 12, Issue 3 , pp 107-119
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Gynaecology, Hospital Foch, Suresnes, France
- 2. Laboratoires Boiron, 20 rue de la Libération, 69110, Sainte Foy-lès-Lyon, France
- 3. Chaire d’Evaluation Médicale Ceren ESC et Dim, CHU Dijon, Dijon, France